Prognostic significance of c‐Met expression in glioblastomas

作者：Doo‐Sik Kong, Sang‐Yong Song, Duk‐Hwan Kim, Kyeung Min Joo, Jin‐San Yoo, Jong Sung Koh, Seung Myung Dong, Yeon‐Lim Suh, Jung‐Il Lee, Kwan Park, Jong‐Hyun Kim, Do‐Hyun Nam · 发表于：Cancer · 年份：2008 · DOI：10.1002/cncr.23972 · 被引用次数：186 · 研究领域：Liver physiology and pathology、Glioma Diagnosis and Treatment、Protease and Inhibitor Mechanisms

BACKGROUND: The authors investigated whether expression of c-Met protein in glioblastomas is associated with overall survival and biologic features representing tumor invasiveness in patients with glioblastomas. METHODS: Paraffin-embedded specimens of glioblastomas from 62 patients treated in a single institution were assessed by immunohistochemical (IHC) analysis of c-Met expression. On the basis of the clinical data for these patients, the association between c-Met expression and clinicobiologic features representing tumor invasiveness was analyzed. RESULTS: c-Met overexpression was detected in 29.0% (18 of 62) of glioblastomas. In patients with c-Met overexpression, the median survival was 11.7 months (95% confidence interval [95% CI], 9.9 months-13.5 months), compared with a median survival of 14.3 months (95% CI, 7.6 months-21.0 months) for patients whose tumors had no or little expression of c-Met (P=.031). On the radiographic analysis, 9 of 18 patients (50%) with tumors overexpressing c-Met demonstrated invasive and multifocal lesions on the initial magnetic resonance images, whereas only 9 of 44 patients (20.5%) with tumors that expressed no or little c-Met demonstrated these features (P=.030). Using immunohistochemistry, we also found a significant association between c-Met expression and matrix metalloproteinase-2,-9 (P=.020 and P=.013). Furthermore, Myc overexpression was found to be closely correlated with c-Met overexpression on IHC analysis (P=.004). CONCLUSIONS...